linjc16/ctgov huggingface dataset:
Electromyographic Assessment of the Shoulder Stabilizing Musculature in CrossFit® Athletes

Study Overview
=================
Brief Summary
-----------------
This is an observational analytical study of prevalent cases and controls.

Detailed Description
-----------------
Approximately 39 subjects who practice CrossFit at least 6 hours a week are invitated to participate in this observational study. It will measure the activation of trapezius and Serratus muscles by Electromyography experiencing a feeling of fatigue 7-8 in PushPress and PullUps.

Official Title
-----------------
Electromyographic Assessment of the Shoulder Stabilizing Musculature in CrossFit® Athletes. An Observational Analytical Study of Case-controls Prevalence

Conditions
-----------------
Muscle Strain, Electromyography, Trapezius Muscle Strain

Intervention / Treatment
-----------------
* Other: observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Practicing CrossFit® for at least 1 year A minimum of 6 hours per week CrossFit® training No shoulder pain at the time of measurement Exclusion Criteria: Tendinitis Bursitis Sistematic disease Nurological disease Central or periferic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: observational|observational electromiographic musculature activation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Observation of Basal Activation in Trapezius and Serratus muscles and after Push-Press and Pull-Up exercises assessed by Electromyographic mDurance® | Trapezius and Serratus muscle activation analysis in CrossFit athletes with Electromyography system for the muscle activity assessment with the electrode tools | 10 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Serratus muscle strain
Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia?

Study Overview
=================
Brief Summary
-----------------
Surgery performed during general anesthesia induces a stress effect on the body. Our plan is to identify population at risk of hyperglycemia during perioperative period.

Detailed Description
-----------------
This is a prospective study to define the relationship between time profile of glucose control before, during and after surgery with patient variables, surgical variables and anesthetic variables. Serum glucose levels will be measured preoperatively and then at 30 minute intervals during surgery. Pain score, pain medication and glucose levels will be measured in the post anesthesia recovery room. Subjects will be contacted 2 weeks following the date of surgery to determine the incidence of postoperative complications.

Official Title
-----------------
Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia

Conditions
-----------------
General Anesthesia, Hyperglycemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective surgery 18-80 years of age Exclusion Criteria: Known diabetics Pregnant patients Cardiac surgery patients Liver transplant patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glucose level at specific points |  | Intraoperatively and in the PACU | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pt telephoned to assess for complications |  | within 2 weeks of surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non diabetic, catabolic energy state
A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects

Study Overview
=================
Brief Summary
-----------------
The principal aim of this study is to obtain safety and tolerability data when PXT002331 is administered orally as single and multiple doses to healthy subjects.

Official Title
-----------------
PXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects

Conditions
-----------------
Parkinson's Disease

Intervention / Treatment
-----------------
* Drug: PXT002331


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects will be; 1.1. males or females of non childbearing potential 1.2. For females, non childbearing potential is defined as follows: permanently sterile following hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or confirmed tubal occlusion (not tubal ligation) postmenopausal, defined as at least 1 year post cessation of menses (without an alternative medical cause) 1.3. of any ethnic origin 1.4. between 18 and 60 years of age, inclusive Subjects will have a 2.1. body mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2, inclusive 2.2. body weight between 50 kg and 100 kg, inclusive Subjects will be in good health, as determined by; 3.1. medical history 3.2. physical examination 3.3. vital signs assessment 3.4. 12 lead ECG and 24 hour Holter Monitoring 3.5. clinical laboratory evaluations (congenital non haemolytic hyperbilirubinaemia is not acceptable) Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PXT002331<br> | Drug: PXT002331<br> <br> |
| Placebo Comparator: Placebo<br> | Drug: PXT002331<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Serious Adverse Events |  | 16 days | 
| Number of clinically relevant signs or symptoms |  | 16 days |
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

Study Overview
=================
Brief Summary
-----------------
In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

Detailed Description
-----------------
In order to improve treatment outcome for cannabis use disorder (CUD), the investigators have developed a laboratory model to investigate the effects of potential treatment medications on cannabis withdrawal and on the subjective and reinforcing effects of cannabis in non treatment-seeking cannabis smokers. In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

Official Title
-----------------
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

Conditions
-----------------
Cannabis Use

Intervention / Treatment
-----------------
* Drug: Lorcaserin
* Drug: Placebo
* Drug: Marijuana


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Current cannabis use Able to give informed consent and perform study procedures Women practicing an effective form of birth control English speaking Exclusion Criteria: Presence of any clinically significant medical diagnoses History of heart disease and cardiac risk factors, severe chronic obstructive pulmonary disease, uncontrolled hypertension, or diabetes Current parole or probation Certain psychiatric diagnoses Current pregnancy or lactation

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lorcaserin + Marijuana<br> | Drug: Lorcaserin<br>* Lorcaserin 10mg BID<br>Drug: Marijuana<br>* Smoked marijuana cigarette<br>|
| Placebo Comparator: Placebo + Marijuana<br> | Drug: Placebo<br>* Placebo capsule BID<br>Drug: Marijuana<br>* Smoked marijuana cigarette<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cannabis Self-administration | Number of cannabis puffs participant chooses to smoke. | 14 days |
Cochlear Implants Registry in Thailand Project

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the outcome of cochlear implant including post operative hearing ability, developing of language, complication from cochlear implant, quality of life, and success factor of cochlear implant.

Official Title
-----------------
Cochlear Implants Registry in Thailand Project

Conditions
-----------------
Cochlear Implantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent surgery with cochlear implant Exclusion Criteria: Patients who reject to participate with this project

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aids Threshold 1 | The pure tone air-conduction threshold at 0.25, 0.5, 1, 2, 3, 4, 6, 8 kilohertz, measuring in the sound-proof room using the standard audiometry while patient is using cochlear implants. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CAP 1 | Categories of Auditory Performance (CAP) is an index consisting of eight performance categories, relating to auditory perception. It is arranged in a hierarchy of skills that increase in difficulty for example from the ability to perceive environmental sounds right up to using the telephone. It is widely used in the range of current research on children with cochlear implants and is an easy to use tool for monitoring progress. | 1 year | 
| Quality of life | The quality of life will be assessed by interviewing questionnaires using HUI-3. | 5 years |
The Genetic and Affective Prediction Study

Study Overview
=================
Brief Summary
-----------------
A major proportion of patients admitted to psychiatric acute and emergency departments have symptoms, behaviors or function influenced by implicit or explicit suicidal intention (tendency towards self-harm, or suicide attempt). There is an increased risk of suicide in the acute phase during in-patient stay and after discharge. At present there is no satisfactory tool to predict post-discharge suicide risk. Multidimensional rating is expected to have better predictive properties than one-dimensional rating for suicidal behavior during in -patient stay and two years after discharge. Multidimensional rating assesses anxiety, panic, agitation, suicidal thoughts and ideations, as well as therapist's reactions during interviews. In the present study the predictive properties of two rating scales for suicidal behavior during in-patient stay and two years after will be compared. One of these is a multidimensional scale: Multidimensional Assessment of Suicide Risk (MARIS).

Official Title
-----------------
The Genetic and Affective Prediction Study

Conditions
-----------------
Mental Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute agitated condition informed consent Exclusion Criteria: Drug abuse in-patient stay for a fixed time at regular intervals

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| acute psychiatric condition<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| self-inflicted, potentially injurious behavior with intention to die defined as acts needing attendance by physician | during in-patient stay | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| suicide |  | 2 years after discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Emergency Services, Psychiatric, Prognosis, Biological markers, Anxiety, Panic, Psychomotor Agitation, Self-injurious Behavior
Non-syndromic Inherited Anomalies of Mineralized Tooth Tissues: a Whole Exome Study to Identify New Pathogenic Variants

Study Overview
=================
Brief Summary
-----------------
ExoDent specifically aims to discover new genes and new mutations causing isolated amelogenesis imperfecta (AI) and dentinogenesis imperfecta (DI) and other dentin anomalies. The key point for clinicians is to distinguish between non syndromic and syndromic disorders in order to improve patients guidance and counseling. To do so, two targeted NGS panel have been designed, one searching for isolated AI and the other for DI. After 18 months, some families remain without any positive results. ExoDent project proposes those negative patients a Whole Exome Sequencing (WES) approach to deeper explore their genetic background.

Official Title
-----------------
Non-syndromic Inherited Anomalies of Mineralized Tooth Tissues: a Whole Exome Study to Identify New Pathogenic Variants

Conditions
-----------------
Amelogenesis Imperfecta, Dentinogenesis Imperfecta, Dentin Anomalies

Intervention / Treatment
-----------------
* Biological: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of amelogenesis imperfecta or dentinogenesis imerfecta or other dentin anomaly with no other signs or symptoms ( familial or isolated) negative results after targeted NGS strategy for molecular diagnosis Exclusion Criteria: absence of positive clinical diagnosis Diagnosis of syndromic disease

Ages Eligible for Study
-----------------
Minimum Age: 4 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: All patients<br>Blood sample | Biological: Blood sample<br>* Adults : 7 to 10 mL Childs : 2 to 4 mL<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genome sequencing | Pathogenic variants identification and qualification | After one day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Amelogenesis imperfecta, Dentinogenesis imperfecta, Dentin anomalies, Whole Exome Study
Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s)

Study Overview
=================
Brief Summary
-----------------
To investigate the association between metabolic syndrome (MS) and thyroid nodule(s).

Detailed Description
-----------------
To investigate the association between metabolic syndrome (MS), body mass index (BMI), hyperglycemia, dyslipidemia, hypertension and thyroid nodule(s) or thyroid functions in euthyroid subjects. Screen for the risk factors that affect the incidence of thyroid nodule(s).

Official Title
-----------------
Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s)

Conditions
-----------------
Metabolic Syndrome, Thyroid Nodule

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People who received routain physical and laboratory examinations in the Health Management Cenre of QianFoShan Hospital from Jan. 2013 to Dec. 2015. signed the informed consent. Have complete clinical data. Exclusion Criteria: Patients with previous history of thyroid disease other than thyroid nodules. People with abnormal thyroid function. Thyroid ultrasound revealed patients with other lesions other than normal thyroid and thyroid nodules. Pregnant or lactating women.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| The MS group<br>Patients with metabolic syndrome(MS). | |
| The non-MS group<br>Patients without metabolic syndrome(MS). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The laboratory examinations | Lipids,glucose,thyroid functions | In 2013-2015 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure of patients in each group |  | In 2013-2015 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
blood pressure, fasting plasma glucose, thyroid stimulating hormone
Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of nefazedone on cocaine self-administration in depressed and non-depressed female cocaine users.

Detailed Description
-----------------
This study evaluated the effect of nefazodone on reducing cocaine use and craving in both depressed and nondepressed women and if there was a greater effect in depressed women.

Official Title
-----------------
Effects of Nefazodone on Treatment of Female Cocaine Abusers

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Nefazodone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females, ages 18-55, minimum use of 8 days of the last 30, minimum of 8th grade education, current diagnosis of cocaine abuse/dependence Exclusion Criteria: Unstable medical illness, dx of MR, OBS, bipolar

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nefazodone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Craving |  |  | 
| Drug use |  |  | 
| Depression |  |  | 
| Life functioning |  |  | 
| HIV risk behaviors |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cocaine dependence
To Study the Effects of Host Genetic Factors on Liver Cirrhosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify genetic determinants of susceptibility to liver cirrhosis . It will assist in predicting individual risks of disease progression and would help to clarify pathophysiologic mechanisms of liver cirrhosis .

Official Title
-----------------
Preventive and Personalized Medicine (2021-2023)

Conditions
-----------------
Liver Cirrhosis

Intervention / Treatment
-----------------
* Genetic: SNP analysis of the DNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hepatitis B Exclusion Criteria: the casual aget of liver disease is not viral infection, such as alcohol abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental group:<br>patients with liver cirrhosis | Genetic: SNP analysis of the DNA<br>* SNP analysis of the DNA obtained from peripheral blood sample<br>|
| Control group<br>patients without liver cirrhosis | Genetic: SNP analysis of the DNA<br>* SNP analysis of the DNA obtained from peripheral blood sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| genotyping for the SNP associated with liver cirrhosis | Genotype frequency of SNP in the study genes of participants and control participants. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SNP